Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-8849, UK.
Allergy Asthma Proc. 2013 Mar-Apr;34(2):170-5. doi: 10.2500/aap.2013.34.3642.
Although data are mixed, asthma and rheumatologic conditions may be associated with cognitive impairment. Medications may play a role because corticosteroids are associated with memory impairment. Therefore, an easily administered assessment of cognition would be useful in these patients. We assessed relationships between self-rated and clinician-rated cognitive performance and mood in patients with asthma and rheumatologic diseases. Participants included 31adults treated for asthma or rheumatologic disorders (17 receiving chronic prednisone therapy, and 14 not receiving prednisone). An objective assessment of a variety of cognitive domains was administered through clinician and patient-rated assessments of cognition. Composite scores for the objective (Global Clinical Rating [GCR]) and subjective (Neuropsychological Impairment Scale: Global Measure of Impairment [GMI]) measures of cognition were derived. Depression was assessed with the 17-item Hamilton Rating Scale for Depression (HRSD-17). A linear regression was conducted with GMI scores as dependent variable and GCR, HRSD-17 scores, and prednisone-use status, as independent variables. Significant differences between prednisone-treated patients and other patients were observed on the GCR, GMI, and HRSD-17. In the regression analysis, HRSD-17 scores, but not GCR scores, significantly predicted GMI scores. Prednisone-treated patients had higher levels of depressive symptoms and subjective and objective cognitive deficits than those not taking prednisone. In the combined patient groups, subjective cognitive assessment was more strongly related to depressive symptoms than objective cognition. Findings suggest physicians should be aware of the potential for cognitive deficits in patients taking corticosteroids and, when appropriate, should consider the use of objective neurocognitive tests or neuropsychology consultation to better characterize its presence and severity.
尽管数据存在差异,但哮喘和风湿性疾病可能与认知障碍有关。药物可能起作用,因为皮质类固醇与记忆障碍有关。因此,对于这些患者,一种易于管理的认知评估将是有用的。我们评估了哮喘和风湿性疾病患者的自我报告和临床医生评定的认知表现和情绪之间的关系。参与者包括 31 名接受哮喘或风湿性疾病治疗的成年人(17 名接受慢性泼尼松治疗,14 名未接受泼尼松治疗)。通过临床医生和患者对认知的评估,对各种认知领域进行了客观评估。通过对客观(全球临床评分[GCR])和主观(神经心理损伤量表:损伤的全球测量[GMI])认知测量的综合评分来得出认知评分。使用 17 项汉密尔顿抑郁评定量表(HRSD-17)评估抑郁。以 GMI 评分为因变量,以 GCR、HRSD-17 评分和泼尼松使用状况为自变量进行线性回归。在 GCR、GMI 和 HRSD-17 上,观察到泼尼松治疗患者与其他患者之间存在显著差异。在回归分析中,HRSD-17 评分,但不是 GCR 评分,显著预测 GMI 评分。接受泼尼松治疗的患者比未服用泼尼松的患者有更高水平的抑郁症状和主观及客观认知缺陷。在合并患者组中,主观认知评估与抑郁症状的相关性强于客观认知。研究结果表明,医生应该意识到服用皮质类固醇的患者存在认知缺陷的可能性,并且在适当的情况下,应该考虑使用客观神经认知测试或神经心理学咨询来更好地描述其存在和严重程度。